Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 Cell

Hepato-Gastroenterology

Volumn 55, Issue 88, 2008, Pages 2178-2183

  Xin, Xiao Min ^a   Li, Gui Qui ^a   Guan, Xiu Ru ^a   Li, Di ^a   Xu, Wei Zhen ^a   Jin, Ying Yu ^a   Gu, Hong Xi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Combination of siRNAs; Covalently closed circular DNA; Hepatitis B virus; RNA interference

Indexed keywords

CIRCULAR DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; MESSENGER RNA; SMALL INTERFERING RNA; VIRUS DNA; VIRUS VECTOR;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; VIRUS INHIBITION; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; PLASMIDS; RNA, SMALL INTERFERING; TRANSFECTION; VIRUS REPLICATION;

EID: 60849131500     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Seeger C, Mason WS. Hepatitis B virus biology Microbiol. Mol. Biol. Rev 2000; 64, 51-68.
2. Beasley R. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1998; 61:1942-1956.
3. Parkin D, Pisani D M, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer1999; 80: 827-841.
4. Parkin D M, Pisani P, Munoz N, Ferlay J. The global health burden of infection associated cancers. Cancer Surv 1999; 33:5-33.
5. Hayashi Y, Koike K. Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA. J Virol 1989; 63:2936-2940.
6. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987; 7: 2745-2752.
7. Lai C L, Chien R N, Leung N W, Chang T T, Guan R, Tai D I, et al. A one-year trial of lamivudine for chronic hepatitis B.N. Engl. J. Med 1998; 339:61-68.
8. Nowak M A, Bonhoeffer S, Hill A M, Boehme R, Thomas H C, Mcdade H. Viral dynamics in hepatitis B virus infection. Proc. Natl.Acad. Sci. USA 1996;93:4398-4402.
9. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antivirall efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol 1998; 9:151-168.
10. Tuttleman J S, Pourcel C, Summers J W. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47:451-460.
11. Rollier C, Sunyach C, Barraud L, Madani N, Jamard C, Trepo C., et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999; 116:658-665.
12. Sophie L P, Pogam L, Chua P K, Newman M, Shih C. Exposure of RNA Templates and Encapsidation of Spliced Viral RNA Are Influenced by the Arginine-Rich Domain of Human Hepatitis B Virus Core Antigen (HBcAg 165-173). J. Virol 2005; 79:1871-1887.
13. Hannon GJ. RNA interference, Nature 2002;418:244-251.
14. Fire A, Xu S, Montgomery M K, Kostas S A, Driver S E, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391:806-811.
15. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol 2003;4:457-467.
16. Lee NS, Dohjima T, Bauer G, Li H, Li M J, Salvaterra P, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol 2002; 20:500-505.
17. Kapadia S B, Brideau A, Andersen, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA 2003; 100:2014-2018.
18. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002; 418:430-434.
19. Jacque J M, Triques K, Stevenson M. Modulation of HIV-1replication by RNA interference. Nature 2002; 418:435-438.
20. Ge Q, McManus M T, Nguyen T, Shen C H, Sharp P A, Eisen H N, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 2003; 100:2718-2723.
21. McCaffrey A P, Nakai H, Pandey K, Huang Z, Salazar F H, Xu H, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol 2003; 21:639-644.
22. Moore M D, McGarvey M J, Russell R A, Cullen B R, McClure M O. Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J. Gene Med 2005; 7:918-925.
23. Morrissey D V, Blanchard K, Shaw L, Jensen K, Lockridge J A, Dickinson B, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005; 41:1349-1356.
24. Uprichard S L, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl. Acad. Sci. USA 2005; 102: 773-778.
25. Maclachlan, Polisky B. Potent and persistent in vivo anti-HBVactivity of chemically modified siRNAs. Nat. Biotechnol 2005; 23:1002-1007.
26. Li G Q, Gu H X, Li D, Xu WZ. Inhibition of Hepatitis B virus cccDNA replication by siRNA. Biochemical and Biophysical Research Communications 2007; 355:398-404.
27. Fu L, Wu X., Kong Y, Wang Y. Regulation of HBV gene expression by core promoter and its upstream sequence. Chin. J. Virol 1997; 13:215-223.
28. Sells M A, Chen M L, Acs G. Production of hepatitis B virus particles in HepG 2 cells transfected with cloned hepatitis B virus DNA Proc Natl Acad Sci USA 1987; 84:1005-1009.
29. Konishi M, Wu C H, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology 2003; 38: 842-850.
30. Ren XR, Zhou LJ, Luo GB, Lin B, Xu A. Inhibition of hepatitis B virus replication in 2.2.15 cells by expressed shRNA. J. Viral Hepatol 2005; 12:236-242.
31. Das A T, Brummelkamp T R, Westerhout E M, Vink M, Madiredjo M, Bernards R, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol 2004; 78:2601-2605.
32. Konishi M, Wu C H, Kaito M, Hayashi K, Watanabe S, Adachi Y, et al. siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. J. Viral Hepat 2006; 13:756-761.
33. Westerhout E M, Ooms M, Vink M, Das A T, Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucl. Acids Res 2005; 33:796-804.
34. Wu H L, Huang L R, Huang CC, Lai H L, Liu C J, Huang YT, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005; 128:708-716.
35. Mohammed KP, Deepak S, Shiv KS, Seemi FB, Khalid J. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-Y.World Journal of Gastroenterology 2005;12:3006-3014.
36. Xuan B Q,Qian Z, Hong J, Huang W. EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs. Virus Res. 2006;11:150-155.
37. Chen Y, Du D, Wu J, Chan Ch P, Tan YQ, Kung HF, et al. Inhibition of hepatitis B virus replication by stably expressed shRNA, Biochemical and Biophysical Research Communications 2003; 311:398-404.
38. Li GQ, Xu WZ, Wang JX, Deng WW, Li D, Gu HX. Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells. Word Journal of Gastroenterology 2007;13:708-716.
39. Schiefke I, IQecker C, Maier M, Oesen U, Etazrodt G, Tannapfel A, et al. Sequential combination therapy of HBe antigen-negative/ virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int 2004; 24:98-104.
40. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro anti-hepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44:551-560.